ZBIO (Zenas BioPharma) Pre-Tax Income : $-156.56 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Zenas BioPharma's pretax income for the three months ended in Dec. 2024 was $-52.18 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-156.56 Mil. Zenas BioPharma's pretax margin was -1,043.50%.

During the past 3 years, Zenas BioPharma's highest Pretax Margin was -73.65%. The lowest was -3131.18%. And the median was -1602.42%.

Zenas BioPharma Pre-Tax Income Historical Data

The historical data trend for Zenas BioPharma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Pre-Tax Income Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Pre-Tax Income

-119.28

-36.82

-156.56

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial				-24.29	-27.80	-37.98	-38.61	-52.18

Competitive Comparison of Zenas BioPharma's Pre-Tax Income

For the Biotechnology subindustry, Zenas BioPharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Zenas BioPharma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Zenas BioPharma's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-163.888	+	7.329	+	0	+	0	+	0
	=	-156.56

Zenas BioPharma's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-55.623	+	3.448	+	0	+	0	+	0
	=	-52.18

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-156.56 Mil.

Zenas BioPharma (NAS:ZBIO) Pre-Tax Income Explanation

Zenas BioPharma's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-52.175	/	5
	=	-1,043.50%

During the past 3 years, Zenas BioPharma's highest Pretax Margin was -73.65%. The lowest was -3131.18%. And the median was -1602.42%.

Zenas BioPharma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.